These results clearly indicated that HVS specifically inhibited the HGF-dependent growth across multiple c-Met-expressing breast cancer cell lines in a dose-responsive manner as compared to their vehicle-treated control groups (Figure 4A). The gene discussed is MET; the disease is breast cancer.